Shire Plc is set to pay $300 million to acquire privately-held Foresight Biotherapeutics Inc which has a late-stage candidate drug for infectious conjunctivitis which is under investigation for both viral and bacterial forms of the disease. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
